NEJM publishes GSK’s Phase IIIb/IV study of ambrisentan and tadalafil to treat PAH patients
The AMBITION study was a randomised, double-blind Phase 3b/4 study designed to compare the efficacy and safety of ambrisentan in combination with tadalafil to monotherapy in treatment-naïve patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.